Table 3.

Empirical Bayes predictors and 95% credibility intervals for the benefit of bupropion to specific non-black patients. Estimation of the benefit for a particular patient requires knowing the patient's average baseline HAM-D17 score (Ȳ_0,ω), the average response score (Ȳ_Q,ω), and the numbers of repeated measures (k_0,ω and k_1,ω). Benefits were multiplied by 100.

(A) k0,ω = 1
		ȲQ,ω =3	ȲQ,ω =10	ȲQ,ω =20	ȲQ,ω =30
Ȳ0,ω =30	k1,ω = 1	39.6 (7.9, 81.2)	20.4 (2.2, 63.9)	5.2 (0.3, 32.0)	0.8 (0.0, 10.4)
	k1,ω = 2	51.8 (16.8, 84.7)	21.8 (3.7, 58.5)	2.4 (0.1, 16.7)	0.1 (0.0, 1.6)
	k1,ω = 3	58.4 (25.0, 85.6)	22.4 (4.9, 55.0)	1.5 (0.1, 10.4)	0.0 (0.0, 0.4)
Ȳ0,ω =20	k1,ω = 1	55.4 (15.6, 86.8)	34.3 (5.8, 75.3)	11.4 (0.9, 48.5)	2.3 (0.1, 19.9)
	k1,ω = 2	61.8 (25.5, 87.6)	31.5 (7.0, 68.8)	5.0 (0.3, 25.4)	0.2 (−0.0, 3.4)
	k1,ω = 3	65.4 (32.4, 87.6)	29.9 (7.7, 63.1)	2.7 (0.2, 15.1)	0.0 (−0.0, 0.7)
Ȳ0,ω =10	k1,ω = 1	59.7 (20.5, 86.1)	44.5 (9.0, 78.7)	19.7 (0.9, 59.4)	4.9 (−1.3, 31.7)
	k1,ω = 2	62.0 (24.9, 86.1)	38.7 (8.6, 72.1)	7.8 (−0.8, 34.3)	0.4 (−1.6, 6.0)
	k1,ω = 3	63.0 (28.2, 85.7)	34.7 (8.4, 66.6)	4.0 (−1.7, 20.6)	0.0 (−1.1, 1.3)
(B) k0,ω = 2
		ȲQ,ω =3	ȲQ,ω =10	ȲQ,ω =20	ȲQ,ω =30
Ȳ0,ω =30	k1,ω = 1	30.8 (5.3, 73.3)	15.3 (1.5, 54.8)	3.9 (0.2, 25.5)	0.6 (0.0, 8.3)
	k1,ω = 2	44.1 (12.9, 79.7)	17.6 (2.8, 51.9)	2.0 (0.1, 14.1)	0.1 (0.0, 1.4)
	k1,ω = 3	52.0 (20.5, 81.9)	19.0 (4.0, 49.6)	1.3 (0.1, 9.1)	0.0 (0.0, 0.4)
Ȳ0,ω =20	k1,ω = 1	53.6 (15.2, 86.6)	33.5 (6.0, 74.6)	12.1 (1.1, 48.6)	2.8 (0.1, 21.2)
	k1,ω = 2	60.8 (24.7, 87.5)	31.1 (7.2, 68.2)	5.5 (0.4, 26.1)	0.3 (−0.0, 4.1)
	k1,ω = 3	64.8 (31.7, 87.7)	29.8 (7.9, 62.6)	3.1 (0.2, 15.9)	0.1 (−0.1, 0.9)
Ȳ0,ω =10	k1,ω = 1	59.8 (21.2, 84.9)	46.3 (9.0, 78.7)	22.9 (−1.0, 61.6)	6.5 (−5.5, 37.0)
	k1,ω = 2	61.3 (24.9, 84.9)	39.8 (7.6, 72.1)	8.9 (−5.0, 37.5)	0.2 (−6.4, 7.8)
	k1,ω = 3	61.9 (28.0, 84.5)	35.3 (6.8, 66.5)	4.1 (−6.7, 22.6)	-0.1 (-5.2, 1.5)